CAR-T Therapy

Phase 1Cell therapy

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

CAR-T Therapy is one of 153 small molecule programs targeting Refractory. It is currently in Phase 1.

Indications

Total Trials

Active Trials

152

Competitors

Pipeline

Status by Indication[3][1]

Indication

RefractoryNot yet recruiting

TreatmentRecruiting

Systemic Lupus ErythematosusRecruiting

VasculitisNot yet recruiting

Acute Lymphoblastic LeukemiaRecruiting

RefractoryPhase 1

Not yet recruiting

TreatmentPhase 1

Recruiting

Systemic Lupus ErythematosusPhase 1

Recruiting

VasculitisPhase 1

Not yet recruiting

Acute Lymphoblastic LeukemiaPhase 1

Recruiting

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

Dexilant

Takeda

Preclinical

2 2

Levulan

Sun Pharmaceutical Industries, Inc.

Preclinical

1 3

Emtriva

Gilead

Preclinical

1 4

Lamprene

Novartis

Preclinical

1 5

Theo-Dur

Pfizer

Preclinical

1 6

Foscavir

CClinigen, Inc.

Preclinical

6 7

CAR-T Therapy

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 1

1 8

Valium

Akero Therapeutics

Preclinical

2 9

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 10

Reminyl

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Not yet recruiting

Refractory

NCT06647329

Phase 1Recruiting

Systemic Lupus Erythematosus

NCT06822881

Q1 2027

Phase 1Recruiting

Refractory

NCT07031713

Phase 1Not yet recruiting

Vasculitis

NCT07033299

Q4 2027

Phase 1Recruiting

Treatment

NCT07280494

Q2 2028

Phase 1Recruiting

Acute Lymphoblastic Leukemia

NCT06752785

Clinical

Trials by Indication[1]

Refractory2 trials

CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors

Not yet recruiting·MMingzhi Zhang·Phase 1·NCT06647329·30 enrolled

Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT07031713·12 enrolled

Lymphoma2 trials

Immunotherapy in Lymphoma

Recruiting·SSung-Soo Park··NCT06796517·72 enrolled

Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma

Unknown status·ZZhao Weili·Phase 1·NCT05979792·35 enrolled

Systemic Lupus Erythematosus1 trial

CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)

Recruiting·—·Phase 1·NCT06822881·27 enrolled

Acute Lymphoblastic Leukemia1 trial

CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.

Recruiting·GGuangzhou Women and Children's Medical Center·Phase 1·NCT06752785·10 enrolled

Treatment Outcome1 trial

Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

Recruiting·SSung-Soo Park··NCT07051850·174 enrolled

2 more indications

Treatment1 trial

To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT

Recruiting·PPeking University People's Hospital·Phase 1·NCT07280494·18 enrolled

Vasculitis1 trial

The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis

Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT07033299·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for CAR-T Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CAR-T Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CAR-T Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Union Hospital, Tongji Medical College, Huazhong University of Science and Technology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

CAR-T Therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q4 2027

Q2 2028

Trials by Indication[1]

Refractory2 trials

Lymphoma2 trials

Systemic Lupus Erythematosus1 trial

Acute Lymphoblastic Leukemia1 trial

Treatment Outcome1 trial

Treatment1 trial

Vasculitis1 trial

References

Drug Info

Quick Facts

Related News